Skip to main content

Abstract Submission FAQs and Guidelines - June 2024 Conference

Important Dates

Abstract Submission
Opens Wednesday, February 7, 2024

Abstract Submission Deadline
Wednesday, May 1, 2024 (11:59 PM ET)

Abstract Acceptance Notifications
Rolling - notifications will be emailed to the submitter's email address within approximately 1 week of abstract submission

Late Breaker Submission Deadline
Tuesday, May 7, 2024 (5:00 PM ET)

Oral Acceptance Notifications (See below for additional requirements if accepted for an Oral Presentation)*
Notification: Week of May 13, 2024

(If accepted, Oral Presentations will be due for CME approval no later than Wednesday, May 29, 2024 (11:59 PM ET).

(Please see below for additional requirements if accepted for an Oral Presentation.)

Final Poster and Abstract for Electronic Posting
Friday, May 31, 2024 (11:59 PM ET)

Important Information Regarding Oral Presentations*

Please be aware of the following dates and requirements in the event you are selected:

A list of abstracts that have been accepted as oral presentations will be posted on the Conference Agenda by Friday, May 17, 2024. *Wednesday, May 29, 2024 (11:59 PM ET) - Presentations must be submitted for CME approval. Format will be PPT. There will be no extensions. More details to follow upon acceptance.

Frequently Asked Questions (FAQs)

Is there an abstract submission fee?
Yes - US $125.00

Are there rules about previous presentations and adaptations of data at conferences and in publications?
Encore and adapted presentations are permitted. All abstracts will undergo review by the Abstract Review Committee who will assess for scientific merit and novelty. The submitting author must provide the name of the conference/publication, presentation/publication date and presentation venue.

Is a trial-in-progress abstract allowed?

Is there an author limit for abstracts?

Is there a word limit or character count to which we should adhere?
600 words; 1 chart or graph is allowed (word count does not include title, authors, author affiliations, references or disclosures)

May a non-author present on behalf of the authors?

  • Yes, for non-accredited poster presentations
  • No, for accredited poster or oral presentations

May an industry employee present on behalf of the authors?

  • Yes, for non-accredited poster presentations
  • No, for accredited poster or oral presentations

Is industry sponsored research allowed?
Yes; however, due to CME guidelines, only non-industry employees will be allowed to present if accepted for an Oral Presentation.

Is society sponsorship required for admission?

Are QR codes allowed on the posters?

Do you have any policy regarding the usage of brand names or trademarks in abstracts or posters?
Brand names, trademarks and logos are NOT allowed - only generic names may be used.

Will you accept an abstract presenting only the study design?
It would be preferable if the abstract included the results/read outs; however, if they are not available at the time of submission but will be presented at the conference, that would be acceptable.

What are the Embargo Rules, if any?

  • None for encore presentations
  • For primary disclosures, scientific dissemination must be reserved until after presentation at the conference. Press releases and media coverage are allowed in advance of the conference provided that data is not included.

Where will the abstracts be published?
All accepted abstracts will be published in the British Journal of Dermatology (BJD) as well as on the RAD Website.

What is the pre-conference abstract availability date/access venue?
Saturday, June 8, 2024 - 7:00 PM (ET)

What is the post-conference abstract availability date/access venue?
In perpetuity

Is there a language requirement for the abstracts?

Abstract Guidelines and Format

As you prepare your submission to the conference, please make note of the following details:

  • All types of atopic dermatitis related research are eligible for submission.
  • Abstract should address scientific questions, detail clinical observations, or contain primary scientific data.
  • Encore presentations of data from previously presented research may be submitted.
  • Abstracts must be submitted in Word format only.
  • Abstracts must be submitted in English only.


  • Please ensure that you include the title, author information including first and last name (middle initial if available), and author institution (name, city, state/province, and country)
  • Titles should be in bold, sentence case
  • Affiliations should be designated with superscript numbers
  • Please include all sections indicated in the Abstract Template
  • Please double-space
  • Word Limit: 600 Words (word count does not include title, authors, author affiliations, keywords, references or disclosures)
  • You may insert one (1) chart or graph. (Note: charts and graphs will be included on the RAD Website; however, they will not be included in the British Journal of Dermatology publicaton.)
Please click below to view the Abstract Template. Abstract format must follow the template provided.

Guidelines for Posters

The following should be completed by Friday, May 31, 2024, at 11:59 PM (ET) and uploaded via the link that will be provided in your acceptance email:

  1. A digital presentation of your poster in high-resolution PDF format must be provided.
    1. Posters may be formatted as:
      1. A conventional poster on a single slide to fit on a 16 x 9 PPT slide
  2. You may also submit an optional 3-minute video presentation of your poster that will be included on the RAD website. Video presentations should be provided in MP4 format.
    1. The presenter should not be an employee of an industry sponsor.
  3. You must agree to present the abstract if it is selected for poster presentation at the RAD Conference. This includes being present during the scheduled time of a poster session. Accepted posters will be accessible to delegates in person in the poster hall and on the RAD website.
  4. Posters/presentations generated by ChatGPT or other artificial intelligence software will not be accepted.

Guidelines for Oral Presentation Authors Should You be Accepted

You will receive notification the week of May 13, 2024, if your abstract has been accepted to be presented as an oral presentation. The following will be required to present during the in-person conference. You may present live or provide a pre-recorded video of your oral presentation. Upon acceptance, you will be assigned a presentation time. Please see below for further details.

Please note: Presentations generated by ChatGPT or other artificial intelligence software will not be accepted.

The presenting author must:

  • Agree to the Confidentiality Policy on behalf of all parties involved with the abstract and communicate this policy to all involved parties. The Confidentiality Policy applies to both standard and late-breaking data submission from the time of abstract submission.
  • You will need to provide your oral presentation slides and disclosure information for CME approval by Wednesday, May 29, 2024 (11:59 PM ET).
    • Oral presentations will be 5-7 minutes.
  • Verify that, if necessary for the work reported, the clinical research represented in the abstract was approved by an appropriate ethics committee or institutional review board and that, if appropriate to the research, informed consent was obtained for all subjects.
  • Verify that all coauthors are aware of the contents of the abstract and support its data.
  • Agree, on behalf of all coauthors, to publication of the abstract in the final scientific program.
  • For an abstract to be included in the final scientific program, it is mandatory for the presenting author to register for the conference and to settle payment within 72 hours of receiving the abstract acceptance. If accepted, you will receive a discount code via your oral presentation acceptance notification email.
  • Agree to present IN PERSON at the RAD Conference in Chicago, IL, if the abstract is selected for Oral Presentation. This includes being present during the scheduled time of the oral session.
  • Agree to list all potential conflicts of interest in the presentation if the abstract is accepted for oral presentation at the RAD Conference.
  • Ensure that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journal Editors.
  • Enter the name of the clinical trial registry and the trial.
If you have any questions or need additional information, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..